New industry association president sets priorities in Spain
This article was originally published in Scrip
An alternative business model for the pharma industry, which is more in tune with the actual needs of health authorities and makes Spain more competitive, is among the priorities of Jesús Acebillo, the new president of the Spanish pharmaceutical industry associationFarmaindustria. He outlined his vision on strengthening the pharmaceutical industry earlier this week during his first public address. Mr Acebillo, president of the NovartisGroup in Spain, said that the industry should act responsibly to keep the national health system sustainable despite the current financial climate, and that better recognition of its innovation and research would continue to be a priority of the association. Mr Acebillo will serve a two-year term, replacing Antoni Esteve, now one of the association's six vice-presidents. The presidency of Farmaindustria rotates between representatives of local and multinational industry.